NCT03568136 - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

May 4, 2020

Study Completion Date

May 4, 2020

Conditions

Dermatitis, AtopicEczema, AtopicNeurodermatitis, Atopic

Interventions

DRUG

Secukinumab 300 mg

Solution for injection in pre-filled syringe

DRUG

Placebo

Solution for injection in pre-filled syringe

Trial Locations (5)

Hannover Medical School, Department for Dermatology, Allergy and Venereology, Hanover

Klinische Forschung Dresden GmbH, Dresden

Carl Gustav Carus University Hospital, Department of Dermatology, Dresden

SRH Wald-Klinikum Gera, Center for Clinical Studies, Gera

SIBAmed Studienzentrum GmbH & Co KG, Leipzig